A Clinical Trial Evaluating the Safety and Efficacy of ABX-EGF in Patients With Hormone Resistant Prostate Cancer With or Without Metastasis

Inclusion Criteria:

- Male 18 years of age or older

- Has tumor tissue available for diagnostics

- Failed front line luteinizing hormone-releasing hormone analogue (LHRH) such as
leuprolide or goserelin, or failed orchiectomy, as evidenced by disease progression.
Patients must continue on a LHRH analogue (unless the patient had an orchiectomy)
throughout the course of the study

- ECOG score of 0 or 1

Exclusion Criteria:

- Any prior chemotherapy for prostate cancer besides hormonal therapy (including no
prior EGFr targeting agent)

- Prior history of cancer other than prostate carcinoma within the past 5 years that
has required treatment or been active (prior basal cell carcinoma is allowed)

- Known to be HIV positive

- Myocardial infarction within one year prior to entering the study